Curated News
By: NewsRamp Editorial Staff
May 01, 2025
Scinai Immunotherapeutics to Host Webinar on Novel Monoclonal Antibody for Rare Skin Conditions
TLDR
- Join Scinai's webinar to gain insights on PC111 monoclonal antibody's treatment potential for rare skin conditions, offering a competitive edge.
- The webinar will cover PC111's mechanism targeting soluble Fas ligand, addressing unmet medical needs with development plans.
- Scinai's focus on developing innovative therapies like PC111 aims to improve healthcare for rare skin conditions, making tomorrow better than today.
- Discover Scinai's cutting-edge approach to treating Pemphigus Vulgaris and SJS/TEN with PC111, a novel monoclonal antibody, in their upcoming webinar.
Impact - Why it Matters
This news matters as it highlights the collaboration between Scinai Immunotherapeutics and Pincell to address unmet medical needs in rare skin conditions. The webinar provides insights into the development plans for PC111, offering hope for patients suffering from Pemphigus Vulgaris and SJS/TEN.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The event follows Scinai’s acquisition of Pincell and a related grant application under Poland’s FENG program.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Scinai Immunotherapeutics to Host Webinar on Novel Monoclonal Antibody for Rare Skin Conditions
